Over the last decade, India has emerged as a significant hub for pharmaceutical outsourcing. The country has moved beyond its traditional role as a generics manufacturing center to develop a diverse Contract Development and Manufacturing Organization (CDMO) ecosystem.
Today, Indian CDMOs support complex active pharmaceutical ingredients (APIs), high-potency compounds, peptide synthesis, biologics manufacturing, and sterile injectable production.
With drug development pipelines becoming increasingly specialized and expensive, outsourcing relationships have evolved from short-term manufacturing agreements to long-term strategic collaborations. India’s CDMO industry is expected to grow, as global pharmaceutical companies diversify supply chains and seek technically capable partners.
Selection Methodology
To ensure balanced evaluation, the companies listed below were assessed using the following parameters:
- Years of operational experience
- International client base
- Regulatory approvals and compliance record
- Breadth of service offerings (APIs, biologics, drug products)
- Manufacturing capacity and infrastructure
- Global operational footprint
Top CDMO Companies in India*
(*Companies listed in no specific ranking order.)
| Company | Founded | Headquarters | Core Services | Key Strengths |
| Neuland Labs | 1984 | Hyderabad | Custom APIs, generic APIs, peptides | Expertise in complex chemistry and peptide development; pure-play API focus; strong regulatory compliance |
| Divi’s Laboratories | 1990 | Hyderabad | Custom synthesis, generic APIs | Large-scale manufacturing capacity; high-potency chemistry; long-standing innovator partnerships |
| Jubilant Pharmova | 1978 | Noida | CRDMO services, sterile injectables | Global CDMO network; expansion of US sterile fill-finish capabilities |
| Syngene International | 1993 | Bengaluru | APIs, biologics, oligonucleotides | Integrated discovery-to-manufacturing services; large scientific workforce |
| Laurus Labs | 2005 | Hyderabad | APIs, formulations | Advanced flow chemistry and biocatalysis capabilities |
| MSN Laboratories | 2003 | Hyderabad | APIs, finished dosage forms | Oncology specialization and strong backward integration |
| Sai Life Sciences | 1999 | Hyderabad | CRDMO services | Strong discovery and process development platform |
| Piramal Pharma Solutions | 1988 | Mumbai | HPAPIs, ADCs, sterile injectables | Specialty modalities and global manufacturing network |
| Hetero Labs | 1993 | Hyderabad | APIs, formulations | Extensive generics portfolio and regulatory approvals |
| Aarti Drugs | 1984 | Mumbai | APIs, intermediates | Multi-chemistry capabilities and integrated supply chain |
Company Profiles
1. Neuland Laboratories Ltd
Founded: 1984
Headquarters: Hyderabad, Telangana
Service Offering:
Neuland Laboratories specializes in the development and manufacturing of complex small-molecule and peptide APIs. The company supports pharmaceutical programs from early research stages through commercial production, including process development and cGMP manufacturing.
Key Capabilities
- Drug development support from laboratory scale to commercial production
- Expertise in complex chemistry and niche molecules
- Dedicated focus on API manufacturing
- Three USFDA and cGMP-compliant facilities
- Reactor capacity exceeding 1,100 KL
- Efficient scale-up from gram quantities to multi-ton production volumes
2. Divi’s Laboratories
Founded: 1990
Headquarters: Hyderabad, Telangana
Service Offering:
Divi’s Laboratories provides custom synthesis and large-scale production of generic APIs, including high-potency compounds.
Key Strengths
- Significant large-scale manufacturing capacity
- Ongoing facility expansions, including developments in Kakinada
- Long-term partnerships with global innovator pharmaceutical companies
3. Jubilant Pharmova Ltd
Founded: 1978
Headquarters: Noida, Uttar Pradesh
Service Offering:
Jubilant Pharmova provides integrated CRDMO and CDMO services covering discovery, API manufacturing, and sterile injectable production.
Key Strengths
- End-to-end development and manufacturing capabilities
- Specialized sterile manufacturing technologies
- Global operational footprint across India, North America, and Europe
4. Syngene International
Founded: 1993
Headquarters: Bengaluru, Karnataka
Service Offering:
Syngene offers integrated research, development, and manufacturing services across small molecules and biologics. Capabilities include ADC development, oligonucleotides, protein sciences, DMPK, toxicology, and cGMP manufacturing.
Key Strengths
- SynVent platform to accelerate early drug discovery
- Extensive international client base
- Strong governance, sustainability, and ESG initiatives
5. Laurus Labs
Founded: 2005
Headquarters: Hyderabad, Telangana
Service Offering:
Laurus Labs provides API manufacturing, formulation development, and CDMO services for small-molecule pharmaceuticals.
Key Strengths
- Expertise in flow chemistry and biocatalysis
- Expansion of R&D facilities
- Strong compliance with global regulatory standards
6. MSN Laboratories
Founded: 2003
Headquarters: Hyderabad, Telangana
Service Offering:
MSN Laboratories offers large-scale API manufacturing and finished dosage form production alongside contract manufacturing services.
Key Strengths
- Multiple high-capacity production facilities
- Strong backward integration
- Oncology-focused product pipeline
7. Sai Life Sciences
Founded: 1999
Headquarters: Hyderabad, Telangana
Service Offering:
Sai Life Sciences provides services spanning discovery chemistry, process development, and commercial manufacturing for small-molecule drugs.
Key Strengths
- Significant investments in Genome Valley infrastructure
- Dual R&D centers supporting innovation
- Integrated discovery-to-manufacturing platform
8. Piramal Pharma Solutions
Founded: 1988
Headquarters: Mumbai, Maharashtra
Service Offering:
Piramal Pharma Solutions provides global CDMO services including high-potency APIs, antibody-drug conjugates (ADCs), and sterile injectable manufacturing.
Key Strengths
- End-to-end development through commercialization
- Expertise in specialized therapeutic modalities
- Manufacturing presence across North America, Europe, and Asia
9. Hetero Labs
Founded: 1993
Headquarters: Hyderabad, Telangana
Service Offering:
Hetero Labs provides APIs, finished formulations, and contract manufacturing services.
Key Strengths
- Strong global generics portfolio
- Multiple regulatory approvals across international markets
- Extensive backward integration
10. Aarti Drugs
Founded: 1984
Headquarters: Mumbai, Maharashtra
Service Offering:
Aarti Drugs manufactures APIs, pharmaceutical intermediates, and provides custom manufacturing solutions.
Key Strengths
- Expertise in multiple chemical processes
- Multi-product manufacturing facilities
- Robust supply-chain integration
Industry Outlook
The Indian CDMO sector is expected to expand steadily over the coming decade. Several emerging trends are shaping the industry:
- Growing demand for peptide and oligonucleotide manufacturing
- Increased outsourcing of antibody-drug conjugates (ADCs) and biologics
- Adoption of digital manufacturing technologies and single-use production systems
Leading CDMO providers continue to expand their global footprint while investing heavily in automation, sustainability, and advanced manufacturing capabilities.
Why India is Emerging as a Global CDMO Hub
India’s rise as a CDMO destination is driven by a combination of cost advantages, regulatory compliance, and a highly skilled scientific workforce.
Key factors include:
Regulatory-approved infrastructure
India hosts more than 350 USFDA-registered pharmaceutical manufacturing facilities, one of the largest numbers outside the US and Europe.
Cost efficiency
Manufacturing in India can reduce production costs by 30–40% compared to Western markets, making outsourcing highly attractive.
Large scientific talent pool
India produces over 200,000 life-science graduates annually, strengthening R&D and manufacturing capabilities.
Strong regulatory and IP frameworks
Indian CDMOs operate under quality systems aligned with international regulatory requirements.
Rapid scale-up capabilities
Investment in modular manufacturing and single-use technologies enables fast expansion for complex drug modalities such as peptides and oligonucleotides.
These advantages position India as a preferred outsourcing destination for global pharmaceutical companies.
Frequently Asked Questions
What is a CDMO?
A CDMO (Contract Development and Manufacturing Organization) provides integrated pharmaceutical services such as drug development, process optimization, scale-up, analytical testing, GMP manufacturing, and regulatory support.
Why do pharmaceutical companies work with CDMOs?
Partnering with CDMOs allows pharmaceutical companies to reduce capital investment, accelerate development timelines, and access specialized manufacturing expertise while maintaining regulatory compliance.
What is the size of the Indian CDMO market?
The Indian CDMO market is expected to exceed USD 30 billion by 2025, driven by increasing outsourcing of APIs, biologics, peptides, and specialized drug formulations.
How should companies choose a CDMO partner in India?
Important evaluation criteria include:
- Regulatory approvals (USFDA, EMA, MHRA)
- Experience with the relevant molecule type
- Manufacturing scale and infrastructure
- Track record with global pharmaceutical clients
- Transparency and robustness of quality systems
What services do Indian CDMOs typically offer?
Common services include:
- API and intermediate manufacturing
- Drug product development
- Biologics and peptide synthesis
- Technology transfer
- Clinical and commercial manufacturing
- Regulatory documentation and filing support
Are Indian CDMOs FDA-approved?
Yes. Many leading CDMOs in India operate USFDA- and EMA-approved manufacturing facilities and supply regulated markets such as the United States, Europe, and Japan.
Which industries rely on CDMO services?
CDMOs support several sectors including:
- Pharmaceutical companies
- Biotechnology firms
- Generic drug manufacturers
- Specialty drug developers
- Contract research organizations (CROs)
Conclusion
India’s CDMO industry is rapidly transforming the global pharmaceutical manufacturing landscape. With strengths spanning complex APIs, biologics, and advanced drug modalities, Indian CDMO companies play a critical role in accelerating drug development while maintaining cost efficiency.
As outsourcing becomes more strategic, selecting the right CDMO partner in India will remain an important decision for pharmaceutical companies seeking reliable long-term collaboration.
